

21 August 2018

NSX Announcement

STRATEGIC PARTNERSHIP WITH I'ROM GROUP

Beroni Group (NSX: BTG) ("Beroni Group") is pleased to announce that it has signed a strategic partnership agreement with I'rom Group Co., Ltd ("I'rom Group"), a company listed on the Tokyo Stock Exchange, to share resources such as technology, research facilities and network of connections ("Agreement"). One of the focus areas of this joint cooperation is in the business of genetic medicine and stem cell engineering using the vector technology owned by a subsidiary of I'rom Group, ID Pharmaceutical Co., Ltd.

Under this Agreement, the parties are able to propose projects and technical development issues, and with consultations from both sides, collaborate in the advancement of stem cell technology and in conducting clinic trials of gene therapy and regenerative medicine. Beroni and I'rom Group may enter into further contractual agreements from time to time as and when the parties agree on specific collaboration projects. One such possible cooperation is in the research and development of regenerative medicine and stem cell therapy to treat cancer tumours.

Beroni Group's Executive Chairman, Mr Jacky Zhang said: "The ability to leverage on I'rom Group's presence in both Japan and Australia with its state-of-the-art clinical research facilities will most certainly strengthen Beroni's undertakings in growing its portfolio of biotechnologies and research initiatives. This cooperation will not only help advance our stem cell therapy technology but also accelerate our R&D clinical trials. It is a privilege to be working with such a leading specialist in the field of regenerative medicine."

Beroni Group will keep the market updated as to the progress of this cooperation arrangement.

About I'rom Group

The I'rom Group was established in Tokyo in April 1997 to conduct pharmaceutical clinical trials. It has since expanded into four business services - Advanced Medicinal Treatment Services, Site Management Organisation Services, Contract Research Organisation Services, and Medical Support Services. The Group has consistently been involved in each of these businesses with the objective of contributing to medical development and elevating the quality of life of patients. It will make further efforts to provide support for clinical trials and for technical developments in advanced medicine.

I'rom Group is focusing its efforts on technical development and subsequent necessary clinical trials in the fields of gene therapy and regenerative medicine. Through its subsidiary, ID Pharmaceutical Co., Ltd, it has built a facility for the manufacture of GMP vector for use in gene therapy and regenerative medicine based on Sendai virus vector technology. The facility can be

used to supply gene therapy formulations and vectors for use in clinical settings. I'rom Group also processes cell cultures under contract for third parties.

In December last year, I'rom Group acquired Australia-based CMAX Clinical Research Pty Ltd, one of Australia's largest and most experienced Phase I-II clinical trial units located in Adelaide. CMAX is a pioneer clinical research center which has extensive practical experience in the support of early stage clinical trials including global large-scale clinical trials and FIH (First-In-Human) trials. Clinical trials have already begun in Australia for a formulation that can be developed for treating limb ischemia.



Figure 1: Signing Ceremony in Japan

For further information please contact:

Mr Jacky Zhang
Executive Chairman
Tel: +86 1851 6931 911
E: 1710426553@qq.com

Mr Peter Wong
Executive Director and CFO
Tel: +61 423 727 580
E: pwong@asiainvest.com.au

About Beroni Group Limited (NSX:BTG) (FSE:6B9)

Beroni Group is a Chinese biotechnological company which is dual listed on the National Stock Exchange (Australia) and Frankfurt Stock Exchange. Its business mainly focuses on biotechnology, life sciences, environmental science and governance, precision medicine, regenerative medicine, and stem cell anti-cancer and anti-aging projects. Beroni Group's overall strategic goal is to have a global presence in the biotechnology, bio-science and environmental science industries.